FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1503438909> ?p ?o ?g. }

• W1503438909 endingPage "3319" @default.
• W1503438909 startingPage "3311" @default.
• W1503438909 abstract "BACKGROUND The primary objective of this study was to determine the safety and maximum tolerated dose (MTD) of the antimesothelin immunotoxin SS1(dsFv)PE38 (SS1P) (a recombinant antimesothelin immunotoxin consisting of a murine antimesothelin variable antibody fragment [Fv] linked to PE38, a truncated portion of Pseudomonas exotoxin A) in combination with pemetrexed and cisplatin in chemotherapy‐naive patients with advanced malignant pleural mesothelioma (MPM). Secondary objectives included tumor response, SS1P pharmacokinetics, and serum biomarkers of response. METHODS Chemotherapy‐naive patients with stage III or IV, unresectable, epithelial or biphasic MPM and normal organ functions were eligible. Pemetrexed (500 mg/m 2 on day 1) and cisplatin (75 mg/m 2 on day 1) were administered every 3 weeks for up to 6 cycles with escalating doses of SS1P administered intravenously on days 1, 3, and 5 during cycles 1 and 2. Tumor response was evaluated every 6 weeks. RESULTS Twenty‐four patients received SS1P at 4 dose levels from 25 to 55 mcg/kg. Grade 3 fatigue was dose‐limiting in 1 patient at 55 mcg/kg. The MTD of SS1P was established as 45 mcg/kg. Other grade 3 toxicities associated with SS1P included hypoalbuminemia (21%), back pain (13%), and hypotension (8%). Of 20 evaluable patients, 12 (60%) had a partial response, 3 had stable disease, and 5 had progressive disease. Of 13 patients who received the MTD, 10 (77%) had a partial response, 1 had stable disease, and 2 had progressive disease. Objective radiologic responses were associated with significant decreases in serum mesothelin ( P =.0030), megakaryocyte potentiating factor ( P =.0005), and cancer antigen 125 ( P < .0001). CONCLUSIONS SS1P given with pemetrexed and cisplatin is safe and well tolerated and exhibits significant antitumor activity in patients with unresectable, advanced pleural mesothelioma. Serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125 levels correlated with objective tumor responses. Cancer 2014;120:3311–3319 . Published 2014. This article is a U.S. Government work and is in the public domain in the USA." @default.
• W1503438909 created "2016-06-24" @default.
• W1503438909 creator A5012741329 @default.
• W1503438909 creator A5022594161 @default.
• W1503438909 creator A5024934444 @default.
• W1503438909 creator A5025737516 @default.
• W1503438909 creator A5027152621 @default.
• W1503438909 creator A5029872582 @default.
• W1503438909 creator A5038066562 @default.
• W1503438909 creator A5044239219 @default.
• W1503438909 creator A5056573254 @default.
• W1503438909 creator A5074644543 @default.
• W1503438909 date "2014-07-02" @default.
• W1503438909 modified "2023-10-16" @default.
• W1503438909 title "Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen" @default.
• W1503438909 cites W1673399330 @default.
• W1503438909 cites W1966272981 @default.
• W1503438909 cites W1971468779 @default.
• W1503438909 cites W1979568379 @default.
• W1503438909 cites W1989906554 @default.
• W1503438909 cites W1995837838 @default.
• W1503438909 cites W2035038195 @default.
• W1503438909 cites W2043477702 @default.
• W1503438909 cites W2065248620 @default.
• W1503438909 cites W2081553250 @default.
• W1503438909 cites W2100576484 @default.
• W1503438909 cites W2100588878 @default.
• W1503438909 cites W2101371847 @default.
• W1503438909 cites W2102627969 @default.
• W1503438909 cites W2108008318 @default.
• W1503438909 cites W2110147320 @default.
• W1503438909 cites W2115543909 @default.
• W1503438909 cites W2118546583 @default.
• W1503438909 cites W2121394047 @default.
• W1503438909 cites W2128903029 @default.
• W1503438909 cites W2139960999 @default.
• W1503438909 cites W2142733460 @default.
• W1503438909 cites W2145112123 @default.
• W1503438909 cites W2150750953 @default.
• W1503438909 cites W2158059172 @default.
• W1503438909 cites W2172175430 @default.
• W1503438909 doi "https://doi.org/10.1002/cncr.28875" @default.
• W1503438909 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6334650" @default.
• W1503438909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24989332" @default.
• W1503438909 hasPublicationYear "2014" @default.
• W1503438909 type Work @default.
• W1503438909 sameAs 1503438909 @default.
• W1503438909 citedByCount "140" @default.
• W1503438909 countsByYear W15034389092014 @default.
• W1503438909 countsByYear W15034389092015 @default.
• W1503438909 countsByYear W15034389092016 @default.
• W1503438909 countsByYear W15034389092017 @default.
• W1503438909 countsByYear W15034389092018 @default.
• W1503438909 countsByYear W15034389092019 @default.
• W1503438909 countsByYear W15034389092020 @default.
• W1503438909 countsByYear W15034389092021 @default.
• W1503438909 countsByYear W15034389092022 @default.
• W1503438909 countsByYear W15034389092023 @default.
• W1503438909 crossrefType "journal-article" @default.
• W1503438909 hasAuthorship W1503438909A5012741329 @default.
• W1503438909 hasAuthorship W1503438909A5022594161 @default.
• W1503438909 hasAuthorship W1503438909A5024934444 @default.
• W1503438909 hasAuthorship W1503438909A5025737516 @default.
• W1503438909 hasAuthorship W1503438909A5027152621 @default.
• W1503438909 hasAuthorship W1503438909A5029872582 @default.
• W1503438909 hasAuthorship W1503438909A5038066562 @default.
• W1503438909 hasAuthorship W1503438909A5044239219 @default.
• W1503438909 hasAuthorship W1503438909A5056573254 @default.
• W1503438909 hasAuthorship W1503438909A5074644543 @default.
• W1503438909 hasBestOaLocation W15034389091 @default.
• W1503438909 hasConcept C104317684 @default.
• W1503438909 hasConcept C112705442 @default.
• W1503438909 hasConcept C115085202 @default.
• W1503438909 hasConcept C126322002 @default.
• W1503438909 hasConcept C142724271 @default.
• W1503438909 hasConcept C143998085 @default.
• W1503438909 hasConcept C159654299 @default.
• W1503438909 hasConcept C182179738 @default.
• W1503438909 hasConcept C185592680 @default.
• W1503438909 hasConcept C203014093 @default.
• W1503438909 hasConcept C2776694085 @default.
• W1503438909 hasConcept C2777045440 @default.
• W1503438909 hasConcept C2777240266 @default.
• W1503438909 hasConcept C2777407522 @default.
• W1503438909 hasConcept C2778239845 @default.
• W1503438909 hasConcept C2778822529 @default.
• W1503438909 hasConcept C2779984678 @default.
• W1503438909 hasConcept C40767141 @default.
• W1503438909 hasConcept C542903549 @default.
• W1503438909 hasConcept C55493867 @default.
• W1503438909 hasConcept C71924100 @default.
• W1503438909 hasConcept C90924648 @default.
• W1503438909 hasConceptScore W1503438909C104317684 @default.
• W1503438909 hasConceptScore W1503438909C112705442 @default.
• W1503438909 hasConceptScore W1503438909C115085202 @default.
• W1503438909 hasConceptScore W1503438909C126322002 @default.
• W1503438909 hasConceptScore W1503438909C142724271 @default.
• W1503438909 hasConceptScore W1503438909C143998085 @default.

• next